论文部分内容阅读
目的:探讨心痛泰颗粒影响高脂诱导载脂蛋白E基因敲除(ApoE-/-)小鼠动脉粥样硬化模型斑块内细胞增殖的作用机制。方法:选取42只4周龄雄性ApoE-/-小鼠,给予高脂饮食喂养,另选取12只C57BL/6J野生型小鼠作为空白组,予普通饲料喂养。8周高脂喂食造模成功后,遵循完全随机设计方法,ApoE-/-小鼠按随机数字表法分4组,模型组、心痛泰颗粒低剂量组、心痛泰高剂量组及阿托伐他汀钙组,空白组为C57BL/6J野生型小鼠。连续6周灌胃给药,在无菌条件下处理动物,采集血清及分离主动脉,高倍显微镜下观察主动脉组织病理变化(斑块面积/动脉壁横切面积),采用罗氏全自动生化分析仪检测血脂指标及IHC法检测PCNA的表达水平。结果:主动脉组织病理变化与模型组比较,治疗组比值均显著降低,差异有统计学意义(P<0.01),其中心痛泰颗粒高剂量组和阿托伐他汀钙组明显优于心痛泰颗粒低剂量组(P<0.01),而心痛泰颗粒高剂量组与他汀组组间差异无统计学意义(P>0.05)。血脂相关指标检测中,心痛泰颗粒低、高剂量组及阿托伐他汀钙组均能显著降低TC、TG、LDL-C,且心痛泰颗粒高剂量组优于低剂量组(P<0.01);但心痛泰颗粒高剂量组与他汀组组间差异无统计学意义(P>0.05)。与模型组比较,心痛泰颗粒低、高剂量组及他汀组均能升高HDL-C,但是这3组间差异无统计学意义(P>0.05)。与模型组比较,心痛泰颗粒能明显下调PCNA阳性表达(P<0.01);且心痛泰颗粒高剂量组优于低剂量组(P<0.05)。结论:心痛泰颗粒能有效干预动脉粥样硬化的形成,缓解斑块内细胞的增殖,可能与心痛泰颗粒可以调节血脂及调控PCNA阳性表达有关。
OBJECTIVE: To investigate the mechanism of Xintongtai Granules in influencing the hyperplasia-induced proliferation of plaques in atherosclerosis model of apolipoprotein E knockout (ApoE-/-) mice. Methods: Forty-two 4-week-old male ApoE-/-mice were selected and fed with a high-fat diet. Another 12 C57BL/6J wild-type mice were selected as blank groups and fed to ordinary diets. After 8 weeks of high-fat feeding, the randomized design method was followed. ApoE-/- mice were divided into 4 groups according to the random number table method. Model group, Xintongtai granules low dose group, Xintongtai high dose group and Atova The statins calcium group and the blank group were C57BL/6J wild-type mice. After 6 weeks of continuous gavage, the animals were treated under aseptic conditions. The serum was collected and the aorta was isolated. The pathological changes of the aorta (plaque area/area of the arterial wall) were observed under high magnification microscope. The Roche automated biochemical analysis was used. The instrument was used to detect blood lipids and IHC to detect the expression of PCNA. RESULTS: Compared with the model group, the pathological changes of the aorta tissue were significantly lower in the treatment group than in the model group (P<0.01). The high-dose group and the atorvastatin calcium group were significantly superior to the Xintongtai granules. Low dose group (P <0.01), and Xintongtai Granule high dose group and statin group, the difference was not statistically significant (P> 0.05). In the test of blood lipid related indicators, Xintongtai Granule low, high dose group and atorvastatin calcium group can significantly reduce TC, TG, and LDL-C, and Xintongtai Granule high dose group is superior to low dose group (P<0.01). However, there was no significant difference in Xintongtai Granule high-dose group and statin group (P>0.05). Compared with the model group, the low-, high-dose, and statin groups of Xintongtai Granules all increased HDL-C, but there was no significant difference between the three groups (P>0.05). Compared with the model group, Xintongtai Granule could significantly down-regulate the positive expression of PCNA (P<0.01), and Xintongtai Granule high-dose group was better than low-dose group (P<0.05). Conclusion: Xintongtai granule can effectively interfere with the formation of atherosclerosis and relieve the proliferation of cells in the plaque. It may be related to Xintongtai granules regulating blood lipids and regulating PCNA positive expression.